Key result
Adding spironolactone to ACEi produces substantial diuresis and clinical improvement in refractory severe CHF.
Why the study?
Severe congestive heart failure refractory to digitalis, high doses of loop diuretics, and converting-enzyme inhibitors lacks effective treatment options.
Does the addition of spironolactone improve clinical and radiological outcomes in patients with severe congestive heart failure refractory to standard therapy?
Case Report (n=3)
Does the addition of spironolactone improve clinical and radiological outcomes in patients with severe congestive heart failure refractory to standard therapy?
Adding spironolactone to ACE inhibitors can induce substantial diuresis and clinical improvement in severe, refractory heart failure, though renal function must be monitored.
Answers are grounded in this paper and cite their sources.
May benefit select refractory HF cases on ACE inhibitors; leaves open confirmation in randomized trials.
Three cases are described of severe congestive heart failure which failed to respond to digitalis, high doses of loop diuretics, and converting-enzyme inhibitors. The addition of spironolactone produced a substantial diuresis associated with clinical and radiological improvement in each case. Although a reversible deterioration in renal function was observed, this drug combination represents a therapeutic option in end-stage heart failure.
No takes yet. Share an insight, caveat, or question.
Ikram et al. (1986) conducted a case report in Refractory severe congestive heart failure (n=3). Spironolactone was evaluated on Diuresis and clinical and radiological improvement. Adding spironolactone to converting-enzyme inhibitors produced substantial diuresis and clinical and radiological improvement in three patients with refractory severe congestive heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: